Lilly Details Retatrutide TRANSCEND-T2D-1 Results

Phase 3 clinical trial results of retatrutide were presented at the 2026 ADA Scientific Sessions.

At the American Diabetes Association (ADA) Scientific Sessions in June 2026, Eli Lilly and Company unveiled landmark findings from its Phase 3 TRANSCEND-T2D-1 clinical trial. The study evaluated retatrutide, an investigational once-weekly triple hormone receptor agonist—a drug that mimics three natural hormones (GIP, GLP-1, and glucagon) to regulate appetite and energy expenditure. These promising clinical results suggest that retatrutide's triple-action approach could open a powerful new door for adults struggling to manage both type 2 diabetes and obesity.

How Was the TRANSCEND-T2D-1 Trial Designed?

To test this next-generation molecule, clinical investigators designed a rigorous, randomized, double-blind, placebo-controlled trial. The study recruited adults living with type 2 diabetes whose blood sugar levels remained high despite maintaining diet and exercise changes. Over a 40-week treatment period, researchers compared several weekly doses of retatrutide (including 4 mg, 9 mg, and 12 mg cohorts) against a placebo to determine if the drug could deliver superior glycemic control and weight reduction.

What Glycemic Reductions Did Patients Achieve at 40 Weeks?

By the end of the trial, participants using retatrutide saw dramatic, dose-dependent improvements in their blood sugar management. Primary clinical outcomes showed that patients achieved average HbA1c reductions between 1.7% and 2.0% across the evaluated doses. In contrast, the placebo group experienced almost no changes in their blood sugar readings.

Key clinical outcomes from the study include:

• Average HbA1c reductions ranging from 1.7% to 2.0% across all evaluated doses.
• Statistically superior blood sugar management compared to the placebo cohort, which showed minimal fluctuations.
• Clinically significant improvements in fasting blood glucose levels by the end of the 40-week study.

These findings show that triple-receptor activation helps optimize natural insulin secretion while regulating glucagon to stabilize blood sugar. For patients, this means more time spent in their target blood glucose range and a lower risk of long-term diabetes complications.

How Much Weight Did Participants Lose on Retatrutide?

In addition to blood sugar control, retatrutide delivered striking weight loss results for participants over the course of the study. Adults assigned to the highest dose of retatrutide (12 mg once weekly) achieved an average body weight reduction of 16.8%. This represents a substantial average drop of 36.6 pounds in just 40 weeks, helping patients move closer to their metabolic goals.

Furthermore, researchers noted that patient weight loss had not hit a plateau by week 40, indicating that weight reduction could continue with longer treatment. Patients also experienced positive shifts in other key cardiovascular risk factors, showing improvements in non-HDL cholesterol, triglycerides, and systolic blood pressure.

What Should Patients Know About Retatrutide's Safety and Side Effects?

Like other incretin-based medications, retatrutide's safety profile is characterized primarily by gastrointestinal symptoms. Participants most commonly reported mild-to-moderate nausea, diarrhea, and vomiting, which occurred mainly during the initial dose-escalation phase and decreased over time. Crucially, the trial's treatment discontinuation rates due to adverse events remained low, ranging between 2.2% and 5.1% across all treatment groups.

The study also revealed that 2.3% to 4.5% of participants experienced mild dysesthesia—a temporary, abnormal sensitivity of the skin to touch. This unusual side effect generally resolved on its own while participants continued their treatment. These results suggest that the majority of patients can successfully tolerate the medication as they work toward their health goals.

What Lies Ahead for Triple Hormone Agonists in Metabolic Medicine?

The rapid evolution of metabolic medicine continues to expand treatment options for patients worldwide. While triple agonists like retatrutide remain under clinical investigation, patients can currently access FDA-approved dual-hormone therapies, including various tirzepatide options, as well as single-hormone agonists like semaglutide. Clinicians at the ADA session stressed that future long-term studies will be crucial to confirm the sustained safety and efficacy of triple-receptor therapies.

If you are looking to address metabolic issues or manage your weight, you should consult with a medical professional. Speak with your doctor today to check if you qualify for current, clinically proven weight management plans.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.